Aquestive Therapeutics (AQST) EBIT Margin (2017 - 2026)
Aquestive Therapeutics (AQST) posted quarterly EBIT Margin of 29.1% for Q1 2026, up 19297.0% year-over-year from N/an in Q1 2025, and down 130.87% quarter-over-quarter from 94.27% in Q4 2025.
Aquestive Therapeutics (AQST) EBIT Margin (2017 - 2026) Analysis & Trends
Aquestive Therapeutics' EBIT Margin history runs 10 years deep, the most recent figure standing at 29.1% for Q1 2026.
- In Q1 2026, EBIT Margin rose 19297.0% year-over-year to 29.1%; the TTM figure through Mar 2026 stood at 838.69% (down 76275.0% YoY), while the FY2025 annual figure was 7574.73%, down 752128.0% from the prior year.
- EBIT Margin for Q1 2026 stood at 29.1%, down from 94.27% in the prior quarter.
- The five-year high for EBIT Margin was 94.27% in Q4 2025, with the low at 222.08% in Q1 2025.
- The 5-year median for EBIT Margin is 74.31% (2024), against an average of 67.49%.
- Peak annual rise in EBIT Margin reached 20870 bps in 2025, while the deepest fall reached 14776 bps in 2025.
- Aquestive Therapeutics' EBIT Margin stood at 100.29% in 2022, then jumped by 70 bps to 29.62% in 2023, then slumped by 286 bps to 114.43% in 2024, then soared by 182 bps to 94.27% in 2025, then tumbled by 131 bps to 29.1% in 2026.
- Business Quant data shows AQST's EBIT Margin at 29.1% in Q1 2026, 94.27% in Q4 2025, and 89.63% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | -5.58% |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 33.91% |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 16.51% |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 42.23% |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 0.17% |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 15.80% |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 18.13% |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Aquestive Therapeutics | 556.36 Mn | 556.36 Mn | 9.80 Mn | -59.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -59.51% |
| Mar 31, 2026 | -29.10% |
| Dec 31, 2025 | 94.27% |
| Sep 30, 2025 | -89.63% |
| Jun 30, 2025 | -113.65% |
| Mar 31, 2025 | -222.08% |
| Dec 31, 2024 | -114.43% |
| Sep 30, 2024 | -61.22% |
| Jun 30, 2024 | 0.27% |
| Mar 31, 2024 | -74.31% |
| Dec 31, 2023 | -29.62% |
| Sep 30, 2023 | -18.28% |
| Jun 30, 2023 | -31.79% |
| Mar 31, 2023 | -41.36% |
| Dec 31, 2022 | -100.29% |
| Sep 30, 2022 | -77.23% |
| Jun 30, 2022 | -159.53% |
| Mar 31, 2022 | -79.36% |
| Dec 31, 2021 | -105.33% |
| Sep 30, 2021 | -59.97% |